This week is Neglected Cancers’ Awareness Week – bringing attention to those rare and less common cancers that are collectively responsible for 1/4 of all cancer patients and have high mortality rates. It is great to see that rare and less common cancers are starting to get the recognition they … Read More
There currently exist few effective treatment options for patients with Advanced Gastro-Oesophageal Cancer (AGOC) that has returned after surgery, or where it is incurable (metastatic) at diagnosis. Chemotherapy can be effective at first, but once the cancer has become resistant to it, the options for treatment are limited. A … Read More
To successfully obtain funding for academic research and the establishment of a clinical trial takes a considerable amount of effort, time and collaboration across multi-disciplinary teams. Follow the genesis of an AGITG clinical trial – MONARCC – from identification of the problem to obtaining funding for a pilot study supported … Read More
The final results of the AGITG ICECREAM trial were presented at this year’s American Society of Clinical Oncology (ASCO) meeting in Chicago on 3 June. Many AGITG members and international colleagues participated in this important study, one of the first prospective trials to limit accrual to pre-defined molecular subsets of colorectal cancer. … Read More
Our latest AGITG Innovation Fund grant, made possible by the generosity of donations raised through our Gutsy Challenge initiative, was awarded to Dr Matthew Burge from the Royal Brisbane and Women’s Hospital. Dr Burge received a $100,000 grant for his MONARCC pilot study, which is focuses on advanced colorectal (bowel) … Read More
Facebook Twitter YouTube